Abstract: Background Bacille Calmette-Guérin (BCG) is routinely given at birth in tuberculosis-endemic settings due to its protective effect against disseminated tuberculosis in infants. BCG is however contraindicated in HIV-infected infants. We investigated whether delaying BCG vaccination to 14 weeks of age affected vaccine-induced antibody responses to Haemophilus influenza type b (Hib)-conjugate, pertussis, tetanus and Hepatitis B (HBV) vaccines, in HIV-exposed uninfected (HEU) andunexposed uninfected (HUU) infants. Methods Infants were randomized to receive BCG at birth or at 14 weeks of age. Blood was taken at 14, 24, and 52 weeks of age and analyzed for Hib, pertussis, tetanus and HBV specific antibodies. Results BCG was given either at birth (106 infants, 51 HEU) or at 14 weeks of age (74 infants, 50 HEU). The timing of BCG vaccination did not influence the antibody response to any antigen studied. However, in a non-randomised comparison, HEU infants had higher Hib antibody concentrations at weeks 14 and 24 (p=0.001 and <0.001 respectively) and pertussis at week 24 (p=0.003). Conversely, HEU infants had lower antibody concentrations to HBV at 14 and 52 weeks (p=0.032 and p=0.031) with no differences in tetanus titres. 
Women with pregnancies of estimated 32 or more weeks gestation were screened for 154 eligibility after routine testing for HIV and written informed consent was obtained. The 155 following were postnatal infant exclusion criteria: stillbirth, birth weight <1.6 kg, severe 156 congenital malformation, asphyxia or other severe illness at birth since under these 157 circumstances, BCG is not routinely given in South Africa. Protocol violators were defined 158 as infants randomized to receive delayed BCG vaccination at 14 weeks, but who were 159 inadvertently given BCG at birth by routine personnel. 160
Study measures and follow-up

161
Infant HIV testing and clinical follow-up were performed as previously described. [ 
23] 162
Briefly, a single infant HIV DNA polymerase chain reaction test (Amplicor, Roche Molecular 163 Diagnostics, Pleasanton , CA) was routinely offered at 6 and at 14 weeks of age. The routine 164 testing algorithm at the time recommended testing at 14 weeks of age only. Follow-up was 165 carried out on the same premises, at the Site B well baby clinic, where infants would have 166 attended routine clinical care. Antibody levels were classified using the following accepted 167 measures. Anti-Hib capsular polysaccharide (PRP-T) IgG antibodies were measured using 168 the VaccZyme TM Human Anti Hib Enzyme Immunoassay kit (MK016, The Binding Site Ltd, 169
Birmingham, England). Measurement of specific IgG antibodies to Bordetella pertussis was 170 completed using pertussis toxin (PT) and filamentous hemagglutinin (FHA) as antigen 171 preparation using the SERION ELISA classic kit (Serion Immundiagnostica GmbH, 172
Würzburg, Germany). Anti-tetanus IgG was measured with the SERION ELISA classic kit 173 (Serion Immundiagnostica GmbH, Würzburg, Germany). Specific IgG against Hepatitis B 174 surface antigen (HBsAg) were quantified using a semi-automated ELISA method (AxSym 
Statistical analysis 191
The primary end point was the difference in the magnitude of antibody responses to Hib, 192 pertussis, HBV and TT between infants in the early and the delayed BCG groups at 14 weeks 193 of age. Secondly, the effect of HIV exposure on vaccine antibody titres was investigated at 194 week 14, 24 and 52. Sample size estimates for this exploratory study were calculated 195 assuming a 30% difference in vaccine antibody responses between BCG vaccinated and 196 unvaccinated infants, and a 30% difference between HIV-exposed and unexposed infants, at 197 week 14. HIV-infected infants (n=2) were excluded from analysis. 
RESULTS
214
120 HIV-infected and 60 HIV-uninfected women were enrolled during pregnancy. Following 215 randomization, 5 infants (2.8%) were excluded; 1 mother withdrew from the study due to 216 geographic relocation and 4 HIV-exposed infants were stillborn. These infants were 217 replaced with additional randomized participants.. 218 Figure 1 provides an overview of the study cohort, per protocol. Randomization of infants 219 resulted in balance for maternal HIV status, infant sex, mean birth weight, maternal CD4+ T 220 cell count and maternal HAART ( Table 1 ). The mean birth weight overall was 3206 grams 221 (standard deviation; SD: 44). Only 6 infants (3.33%) had birth weight <2500 grams. The 222 mean maternal CD4+ T lymphocyte amongst HIV-infected women was 363 cells/mm 3 (SD 223 23.7). Of HIV-infected women, 27 (15%) had a CD4+ T lymphocyte count ≤200 cells/mm 3 ; 224 these women were all on highly active antiretroviral therapy (HAART; Zidovudine, 225
Lamivudine and Nevirapine). 226
Of the 90 infants randomized to delayed BCG, 16 were inadvertently given immediate BCG 227 by routine labour ward personnel, resulting in 106 infants in the birth (67, 63.2% HIV-228 exposed) and 74 infants (46, 62.2% HIV-exposed) in the delayed BCG groups, respectively. 229
Analysis was therefore based on actual vaccination (per protocol) status. 230
Proportion of infants with positive/protective antibody concentrations 231
Proportions of infants with "protective" antibody concentrations to Hib, pertussis, TT and 232 HBV are reflected in Supplementary Table 2. In general, the proportion of infants with 233 "protective" Hib and pertussis titres was low at all timepoints. Only 62% of infants had 234 antibody concentrations to Hib correlating with protective immunity at week 24, following 235 verified completion of weeks 6, 10 and 14 vaccinations; the level declined to 35% at week 236 52. At week 24, 48% of infants had positive pertussis titres; 45% of infants maintained 237 positive titres at week 52. In contrast, the proportion of infants with positive/protective 238 titres to TT and HBV vaccines was high with all infants having antibody concentrations 239 correlating with sufficient or long-term protective immunity to tetanus vaccine at week 24; 240 positive responses to HBV were detected in all infants. Only 1.2% of infants lacked 241 protective response to TT at week 52. 242
Effect of BCG vaccination timing on antibody concentrations 243
Overall, there was no detectable effect of BCG vaccination timing on the GMC antibody titres 244 to Hib, pertussis, or TT at weeks 14, 24 or 52 (Figure 2 ). There was a trend for higher 245 antibody responses to HBV in the birth BCG group at week 14 (GMC in birth group: 30.5 vs. 246 10.1in the delayed group; p=0.090). Similarly, there was no observed effect of BCG on the 247 proportion of infants with "protective" antibody concentrations (Supplementary Table 1) . 248
Results were similar comparing the proportion of infants with "protective" responses in the 249 birth and delayed BCG groups at 14 weeks when infants in the protocol violator group were 250 excluded (data not shown). 251
Effect of in utero HIV exposure on antibody concentrations 252
Stratified analysis of antibody titres between HIV-exposed and unexposed infants produced 253 similar results in both the birth and delayed BCG groups (data not shown); the birth and 254 delayed groups were therefore combined for further analysis. In the combined analysis, 255
HIV-exposed infants consistently demonstrated higher GMC antibody titres to Hib at weeks 256 14 and 24, and also to pertussis at week 24 (Figure 3a-b) . These higher concentrations 257 corresponded to a higher proportion of HIV-exposed infants with positive/protective 258 antibody concentrations to Hib at week 14 (OR: 1.75; 95% CI: 1.17-2.63, p=0.007) and week 259 24 (OR: 2.09; 95% CI: 1.37-3.17, p=0.001) and to pertussis at week 24 (OR: 1.80; 95% CI: 260 1.19-2.72, p=0.007) ( Table 2) . Conversely, HIV-exposed infants had significantly lower GMC 261 of HBV antibody at week 14 and week 52, although all were above positive/protective 262 concentrations (Figure 3d ). Antibody concentrations to tetanus vaccine were similar 263 between HIV-exposed and unexposed infants (Figure 3c) . 264
Effect of BCG vaccination timing on antibody concentrations in HIV-exposed infants 265
Because delaying BCG vaccination until 14 weeks of age would be most relevant for infants 266 born to HIV-positive mothers, we compared the effects of BCG vaccination at birth versus 267 14 weeks of age in HIV-exposed infants. There was no detectable effect of BCG vaccination 268 on the GMC of antibody to Hib, pertussis, tetanus of HBV at weeks 14, 24, or 52 269 (Supplementary Figure 1) . 270
Predictors of antibody titres against against Hib and pertussis 271
In a multivariable base-10 linear regression model with log10-transformed values for 272 factors (including BCG vaccination as primary predictor and HIV exposure status, birth 273 weight and sex as covariates) associated with "protective" anti-Hib concentration at 14 274 weeks of age (including BCG vaccination as primary predictor and HIV exposure status, 275 birth weight and sex as covariates), only HIV exposure remained associated with higher 276 concentrations (coefficient 0.47; 95% CI: 0.21-0.72; p<0.001; adjusted R 2 =0.101) (Table 3) ; 277 the timing of BCG vaccination was not a predictor. In a similar model for pertussis, none of 278 the predictors were associated with "protection" against pertussis at week 14 (adjusted 279 R 2 =0.020; Table 3 (comparing the effect of BCG given at birth to infants who had not yet received BCG), and at 297 24 and 52 weeks (comparing the effect of BCG given at birth to BCG given at 14 weeks). In a 298
non-randomised comparison, we found that HIV-exposed infants had significantly higher 299 antibody concentrations to pertussis and Hib than HIV-unexposed infants, following 300
vaccination. This study is limited by the lack of data on maternal and baseline (birth) infant 301 antibody responses, and a lack of correlation with clinical endpoints. The protocol 302 violations (vaccination with BCG when subjects were randomized to the delayed BCG 303 group) and high loss to follow-up may also have introduced bias. We did not find any 304 differences at birth in sex, birth weight, or maternal HIV status between infants in the 305 protocol deviation group, and infants who were vaccinated as per randomisation schedule, 306 but this does not exclude bias (for example, if loss to follow-up was associated with 307 differences in response to immunization). 308
We found that the proportion of children with Hib antibody >1 mg/ml were consistently of 309 greater magnitude amongst HEU compared to HUU infants in both the early and delayed 310 vaccination groups and remained significant after controlling for the timing of BCG 311 vaccination, birth weight and sex, at week 14. The proportion of children with anti-312 pertussis antibody >30 FDA-U/ml at 24 weeks of age was also higher amongst HIV-exposed 313 infants. These data are consistent with our own and other published data. [37] In this study, we have no data on prevaccination antibody levels, and therefore 330 cannot distinguish whether HEU infants had poor antibody responses due to inherent 331 deficiencies in immunity, or due to differences in passive maternal antibody levels. effects (neither of which were assessed in this study). Although antibody responses to Hib 368 and pertussis were higher amongst HIV-exposed than HIV-unexposed infants, they were not 369 "protective" in a third of infants by 52 weeks of age. These findings support further 370 investigation into optimizing infant vaccination strategies in settings with high HIV 371 prevalence. 372
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